Monica Gandhi1, Peter Bacchetti, Matthew A Spinelli1, Hideaki Okochi2, Jared M Baeten3, Oraphan Siriprakaisil4, Virat Klinbuayaem4, Warren C Rodrigues5, Guohong Wang5, Michael Vincent5, Tim R Cressey6,7,8, Paul K Drain3. 1. Division of HIV, Infectious Disease, and Global Medicine, Department of Medicine, University of California, San Francisco (UCSF), San Francisco, CA. 2. Bioengineering and Therapeutic Sciences, UCSF, San Francisco, CA. 3. Departments of Global Health, Medicine and Epidemiology, University of Washington, Seattle, WA. 4. Department of Medicine, Sanpatong Hospital, Sanpatong, Chiang Mai, Thailand. 5. Immunoanalysis Division, Alere Rapid Diagnostics, Abbott Rapid Diagnostics Division (ARDx), Pomona, CA. 6. Department of Medicine, Chiang Mai University, Chiang Mai, Thailand. 7. Department of Immunology and Infectious Diseases, Harvard T.H Chan School of Public Health, Boston, MA. 8. Department of Molecular and Clinical Pharmacology, University of Liverpool, United Kingdom.
Abstract
BACKGROUND: Current pharmacologic adherence monitoring for antiretrovirals involves expensive, labor-intensive liquid chromatography/tandem mass spectrometry (LC-MS/MS)-based methods. Antibody-based assays can monitor and support adherence in real time. We developed a tenofovir (TFV)-based immunoassay and further validated it in a directly observed therapy (DOT) study. DESIGN: Pharmacologic DOT study of TFV disoproxil fumarate (TDF)/emtricitabine (FTC) administered to HIV-noninfected volunteers. METHODS: The TARGET study provided directly observed TDF 300 mg/FTC 200 mg 7 (high adherence), 4 (moderate), and 2 doses/week (low) to 30 volunteers (10/group) in Thailand, collecting a total of 637 urine samples over 6 weeks of administration and during washout. ELISA measured urine TFV levels by the immunoassay and LC-MS/MS-based concentrations served as the gold standard. A mixed-effects regression model evaluated cutoffs for a point-of-care assay. Performance characteristics of the immunoassay were compared with LC-MS/MS at a chosen cutoff. RESULTS: Median TFV levels were 12,000 ng/mL by the immunoassay 1 day after dosing; 5000 ng/mL 2 days after dosing; 1500 ng/mL 3 days after dosing; and below the lower limit of quantification thereafter (≥4 days). An immunoassay cutoff of 1500 ng/mL accurately classified 98% of patients who took a dose 24 hours ago as adherent. The specificity and sensitivity of the immunoassay compared with LC-MS/MS at the 1500 ng/mL cutoff were 99% and 94%; the correlation between TFV levels by the 2 assays was high (0.92, P < 0.00001). CONCLUSIONS: We have developed a novel TFV immunoassay that is highly specific, sensitive, and correlates strongly with LC-MS/MS measurements in a large DOT study. Adherence benchmarks from this DOT study will guide the development of a low-cost rapid point-of-care test for pre-exposure prophylaxis and antiretroviral treatment adherence monitoring and interventions.
BACKGROUND: Current pharmacologic adherence monitoring for antiretrovirals involves expensive, labor-intensive liquid chromatography/tandem mass spectrometry (LC-MS/MS)-based methods. Antibody-based assays can monitor and support adherence in real time. We developed a tenofovir (TFV)-based immunoassay and further validated it in a directly observed therapy (DOT) study. DESIGN: Pharmacologic DOT study of TFVdisoproxil fumarate (TDF)/emtricitabine (FTC) administered to HIV-noninfected volunteers. METHODS: The TARGET study provided directly observed TDF 300 mg/FTC 200 mg 7 (high adherence), 4 (moderate), and 2 doses/week (low) to 30 volunteers (10/group) in Thailand, collecting a total of 637 urine samples over 6 weeks of administration and during washout. ELISA measured urine TFV levels by the immunoassay and LC-MS/MS-based concentrations served as the gold standard. A mixed-effects regression model evaluated cutoffs for a point-of-care assay. Performance characteristics of the immunoassay were compared with LC-MS/MS at a chosen cutoff. RESULTS: Median TFV levels were 12,000 ng/mL by the immunoassay 1 day after dosing; 5000 ng/mL 2 days after dosing; 1500 ng/mL 3 days after dosing; and below the lower limit of quantification thereafter (≥4 days). An immunoassay cutoff of 1500 ng/mL accurately classified 98% of patients who took a dose 24 hours ago as adherent. The specificity and sensitivity of the immunoassay compared with LC-MS/MS at the 1500 ng/mL cutoff were 99% and 94%; the correlation between TFV levels by the 2 assays was high (0.92, P < 0.00001). CONCLUSIONS: We have developed a novel TFV immunoassay that is highly specific, sensitive, and correlates strongly with LC-MS/MS measurements in a large DOT study. Adherence benchmarks from this DOT study will guide the development of a low-cost rapid point-of-care test for pre-exposure prophylaxis and antiretroviral treatment adherence monitoring and interventions.
Authors: Barbara S Mensch; Elizabeth R Brown; Karen Liu; Jeanne Marrazzo; Zvavahera Mike Chirenje; Kailazarid Gomez; Jeanna Piper; Karen Patterson; Ariane van der Straten Journal: AIDS Behav Date: 2016-11
Authors: Monica Gandhi; Pamela M Murnane; Peter Bacchetti; Richard Elion; Michael A Kolber; Stephanie E Cohen; Howard Horng; Alexander Louie; Karen Kuncze; Catherine A Koss; Peter L Anderson; Susan Buchbinder; Albert Liu Journal: AIDS Date: 2017-10-23 Impact factor: 4.177
Authors: Karen L Margolis; Stephen E Asche; Anna R Bergdall; Steven P Dehmer; Sarah E Groen; Holly M Kadrmas; Tessa J Kerby; Krissa J Klotzle; Michael V Maciosek; Ryan D Michels; Patrick J O'Connor; Rachel A Pritchard; Jaime L Sekenski; JoAnn M Sperl-Hillen; Nicole K Trower Journal: JAMA Date: 2013-07-03 Impact factor: 56.272
Authors: Michael M Givertz; Lynne W Stevenson; Maria R Costanzo; Robert C Bourge; Jordan G Bauman; Gregg Ginn; William T Abraham Journal: J Am Coll Cardiol Date: 2017-10-10 Impact factor: 24.094
Authors: Catherine A Koss; Sybil G Hosek; Peter Bacchetti; Peter L Anderson; Albert Y Liu; Howard Horng; Leslie Z Benet; Karen Kuncze; Alexander Louie; Parya Saberi; Craig M Wilson; Monica Gandhi Journal: Clin Infect Dis Date: 2018-01-06 Impact factor: 9.079
Authors: Deborah Donnell; Jared M Baeten; Namandjé N Bumpus; Justin Brantley; David R Bangsberg; Jessica E Haberer; Andrew Mujugira; Nelly Mugo; Patrick Ndase; Craig Hendrix; Connie Celum Journal: J Acquir Immune Defic Syndr Date: 2014-07-01 Impact factor: 3.731
Authors: Maureen J Kimulwo; Javan Okendo; Rashid A Aman; Bernhards R Ogutu; Gilbert O Kokwaro; Dorothy J Ochieng; Anne W T Muigai; Florence A Oloo; Washingtone Ochieng Journal: PLoS One Date: 2017-02-24 Impact factor: 3.240
Authors: Tim R Cressey; Oraphan Siriprakaisil; Rachel W Kubiak; Virat Klinbuayaem; Pra-Ornsuda Sukrakanchana; Justice Quame-Amaglo; Hideaki Okochi; Yardpiroon Tawon; Ratchada Cressey; Jared M Baeten; Monica Gandhi; Paul K Drain Journal: Int J Infect Dis Date: 2020-06-14 Impact factor: 3.623
Authors: Matthew A Spinelli; Jessica E Haberer; Peter R Chai; Jose Castillo-Mancilla; Peter L Anderson; Monica Gandhi Journal: Curr HIV/AIDS Rep Date: 2020-08 Impact factor: 5.071
Authors: Pamela M Murnane; Peter Bacchetti; Judith S Currier; Sean Brummel; Hideaki Okochi; Nhi Phung; Alexander Louie; Karen Kuncze; Risa M Hoffman; Teacler Nematadzira; Dean K Soko; Maxensia Owor; Friday Saidi; Patricia M Flynn; Mary G Fowler; Monica Gandhi Journal: AIDS Date: 2019-08-01 Impact factor: 4.177
Authors: Paul K Drain; Ashley R Bardon; Jane M Simoni; Tim R Cressey; Pete Anderson; Derin Sevenler; Ayokunle O Olanrewaju; Monica Gandhi; Connie Celum Journal: Curr HIV/AIDS Rep Date: 2020-10 Impact factor: 5.071
Authors: Jesse Clark; Sari Reisner; Amaya Perez-Brumer; Leyla Huerta; Hugo Sanchez; Kathleen Moriarty; Maria Mamani Luque; Hideaki Okochi; Ximena Salazar; Matthew Mimiaga; Jorge Sanchez; Monica Gandhi; Kenneth H Mayer; Javier R Lama Journal: AIDS Behav Date: 2021-01-01